Hepatitis C virus infection

Clinical Microbiology and Infection

Volumn 11, Issue 2, 2005, Pages 86-94

  Thomson, Brian J ^a,b   Finch, R G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Epidemiology; Extra hepatic disease; Hepatitis C virus; Liver disease; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACUTE HEPATITIS; ALCOHOL CONSUMPTION; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROL STRATEGY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HEALTH PROMOTION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERDISCIPLINARY COMMUNICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MASS SCREENING; MITOCHONDRIAL TOXICITY; MOLECULAR BIOLOGY; MONOTHERAPY; PATHOGENESIS; PATIENT CARE; PATIENT EDUCATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PRISONER; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED KINGDOM; VIRUS CARRIER; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION; VIRUS VIRULENCE;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 13844267622     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01061.x     Document Type: Review

References (43)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
2. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
3. Department of Health. Hepatitis C strategy for England. Department of Health, 2002. Available at: http://www.doh.gov.uk/assetRoot/04/07/59/86/04075986.pdf.
4. Poynard T, Bedossa P, Opolon P et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
5. Tong MJ, el-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
6. Detre KM, Belle SH, Lombardo M. Liver transplantation for chronic viral hepatitis. Viral Hep Rev 1997; 2: 219-228.
7. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001; 313: 451-464.
8. Ray RB, Ray R. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol Lett 2001; 202: 149-156.
9. Lasarte JJ, Sarobe P, Boya P et al. A recombinant adenovirus encoding hepatitis C core and E1 proteins protects mice against cytokine induced liver damage. Hepatology 2003; 37: 461-470.
10. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48: 707-713.
11. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003; 84: 274-286.
12. Anonymous. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47: 1-39.
13. Vandelli C, Renzo F, Romano L et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10 year prospective follow-up study. Am J Gastroenterol 2004; 99: 855-859.
14. Ghosn J, Pierre-Francois S, Thibault V et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004; 5: 303-306.
15. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG 2001; 108: 371-377.
16. Ryder SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451-455.
17. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
18. Fontaine H, Nalpas B, Poulet B et al. Hepatitis activity index is a key factor in determining the natural history of hepatitis C. Hum Pathol 2001; 32: 904-909.
19. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.
20. Hourigan LF, MacDonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219.
21. Rubbia-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-412.
22. Kumar D, Farrell GC, Fung C et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002; 36: 1266-1272.
23. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 45: 744-749.
24. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
25. Kuper H, Ye W, Broome U et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism or cirrhosis. Hepatology 2001; 34: 714-718.
26. Planas R, Balleste B, Alvarez MA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823-830.
27. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40: 341-352.
28. Saracco G, Olivero A, Ciancio A, Carenzi S, Rizzetto M. Therapy of chronic hepatitis C: a critical review. Curr Drug Targets Infect Disord 2003; 3: 25-32.
29. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
30. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
31. Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
32. Jeffers LS, Cassidy W, Howell C, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-1708.
33. Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023.
34. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
35. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88.
36. Nomura H, Suketo S, Tanimoto H et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39: 1213-1219.
37. Nelson M, Matthews G, Brook M et al. BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. HIV Med 2003; 4: 52-62.
38. Dieterich DT, Kaplowitz N, Becker S et al. Hepatic safety and HAART. Clin Infect Dis 2004; 38(suppl 2): S43-S113.
39. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
40. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med 2004; 351: 451-459.
41. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003; 52: 1500-1504.
42. Department of Health. Hepatitis C action plan for England Department of Health, 2004. Available at: http://www.dh.gov.uk/assetRoot/04/08/47/13/04084713.pdf.
43. Sypsa V, Touloumi G, Tassopoulos NC et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepatitis 2004; 11: 366-374.